$2.28 Earnings Per Share Expected for United Therapeutics Co. (NASDAQ:UTHR) This Quarter

Wall Street analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings per share of $2.28 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $2.52 and the lowest estimate coming in at $2.04. United Therapeutics reported earnings per share of $3.63 in the same quarter last year, which would suggest a negative year-over-year growth rate of 37.2%. The business is scheduled to report its next earnings report on Wednesday, July 29th.

On average, analysts expect that United Therapeutics will report full-year earnings of $10.40 per share for the current fiscal year, with EPS estimates ranging from $9.23 to $12.20. For the next fiscal year, analysts expect that the company will report earnings of $10.42 per share, with EPS estimates ranging from $8.66 to $11.86. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.69. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The business had revenue of $356.30 million for the quarter, compared to analysts’ expectations of $343.68 million. During the same quarter last year, the company earned $3.58 EPS. The business’s revenue was down 1.7% on a year-over-year basis.

UTHR has been the subject of a number of recent analyst reports. Jefferies Financial Group raised United Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $115.00 to $123.00 in a research report on Tuesday, March 10th. They noted that the move was a valuation call. ValuEngine raised United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 25th. HC Wainwright boosted their target price on United Therapeutics from $85.00 to $125.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a research note on Sunday, May 3rd. Finally, TheStreet upgraded United Therapeutics from a “c” rating to a “b” rating in a research note on Wednesday, April 29th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. United Therapeutics currently has a consensus rating of “Buy” and an average price target of $137.00.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 10,000 shares of United Therapeutics stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $115.90, for a total transaction of $1,159,000.00. Following the sale, the chief executive officer now owns 10,140 shares of the company’s stock, valued at approximately $1,175,226. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Judy D. Olian sold 4,510 shares of United Therapeutics stock in a transaction on Monday, June 8th. The shares were sold at an average price of $124.96, for a total value of $563,569.60. Following the sale, the director now directly owns 3,490 shares in the company, valued at approximately $436,110.40. The disclosure for this sale can be found here. In the last three months, insiders sold 207,610 shares of company stock worth $24,546,906. Company insiders own 10.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Altshuler Shaham Ltd bought a new stake in United Therapeutics during the 1st quarter valued at $28,000. Chevy Chase Trust Holdings Inc. acquired a new position in shares of United Therapeutics during the 4th quarter valued at $31,000. NWK Group Inc. acquired a new position in shares of United Therapeutics during the 4th quarter valued at $35,000. Sowell Financial Services LLC increased its position in shares of United Therapeutics by 149.0% during the 4th quarter. Sowell Financial Services LLC now owns 732 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 438 shares during the period. Finally, First Mercantile Trust Co. acquired a new position in shares of United Therapeutics during the 1st quarter valued at $72,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

UTHR stock traded down $0.27 during midday trading on Thursday, reaching $119.96. The stock had a trading volume of 5,788 shares, compared to its average volume of 650,721. United Therapeutics has a 52-week low of $74.31 and a 52-week high of $127.79. The company has a current ratio of 8.91, a quick ratio of 8.46 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $118.80 and its 200 day simple moving average is $102.01. The company has a market cap of $5.27 billion, a price-to-earnings ratio of 10.01 and a beta of 0.87.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: Recession

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.